{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:20:05Z","timestamp":1786504805670,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2017.00091","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T11:07:24Z","timestamp":1486465644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague"],"prefix":"10.3389","volume":"8","author":[{"given":"Karleigh A.","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay B.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carwyn","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah V.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0169-409X(88)90007-5","article-title":"Mononuclear phagocyte system macrophages as targets for delivery of liposome-encapsulated antimicrobial agents.","volume":"2","author":"Alving","year":"1988","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B2","first-page":"250","article-title":"Plague in Madagascar: overview of the 2014-2015 epidemic season.","volume":"90","author":"Bertherat","year":"2015","journal-title":"Wkly. Epidemiol. Rec."},{"key":"B3","first-page":"73","article-title":"\u201cInhaled liposomal ciprofloxacin: once a day management of respiratory infections,\u201d in","author":"Bruinenberg","year":"2010","journal-title":"Respiratory Drug Delivery 2010"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S1569-1993(09)60196-X","article-title":"Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients.","volume":"8(Suppl. 2)","author":"Bruinenberg","year":"2009","journal-title":"J. Cystic Fibros."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/03639040801958421","article-title":"Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects.","volume":"34","author":"Chono","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"6","key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections.","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"key":"B7","first-page":"409","article-title":"Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance,\u201d in","author":"Cipolla","year":"2010","journal-title":"Respiratory Drug Delivery 2010"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/AAC.41.6.1288","article-title":"Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.","volume":"41","author":"Conley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archinte.1992.00400180107017","article-title":"Plague. A clinical review of 27 cases.","volume":"152","author":"Crook","year":"1992","journal-title":"Arch. Intern. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s15010-005-8209-8","article-title":"Immunomodulatory activities of fluoroquinolones.","volume":"33","author":"Dalhoff","year":"2005","journal-title":"Infection"},{"key":"B12","first-page":"437","article-title":"A mobile form of the Henderson apparatus.","volume":"67","author":"Druett","year":"1969","journal-title":"Epidemiol. Infect."},{"key":"B13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1152\/ajplegacy.1947.150.1.70","article-title":"Measurement of the respiratory volumes of laboratory animals.","volume":"150","author":"Guyton","year":"1947","journal-title":"Am. J. Physiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1128\/AAC.02555-13","article-title":"Liposome-encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis Schu S4 strain.","volume":"58","author":"Hamblin","year":"2014a","journal-title":"Antimicrob. Agents Chemother."},{"issue":"79","key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2014.00079","article-title":"The potential of liposome\u2013encapsulated ciprofloxacin as a tularemia therapy.","volume":"4","author":"Hamblin","year":"2014b","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B16","first-page":"372","article-title":"The respiratory retention of bacterial aerosols: experiments with radioactive spores.","volume":"51","author":"Harper","year":"1953","journal-title":"Epidemiol. Infect."},{"key":"B17","author":"Harris","year":"1993","journal-title":"Factories of Death: Japanese Biological Warfare, 1932-1945 and the American Cover-Up."},{"issue":"731604","key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/731604","article-title":"Advanced development of the rF1V and rBV A\/B vaccines: progress and challenges.","volume":"2012","author":"Hart","year":"2012","journal-title":"Adv. Prev. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1128\/AAC.02504-12","article-title":"Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB\/c mice.","volume":"57","author":"Heine","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1128\/AAC.02420-14","article-title":"Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.","volume":"58","author":"Heine","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon: medical and public health management.","volume":"283","author":"Inglesby","year":"2000","journal-title":"J. Am. Med. Assoc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1128\/AAC.36.5.993","article-title":"Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.","volume":"36","author":"Lettieri","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1128\/AAC.03443-14","article-title":"Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.","volume":"58","author":"Norville","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","first-page":"89","article-title":"Plague around the world.","volume":"91","author":"Organisation","year":"2016","journal-title":"Wkly. Epidemiol. Rec."},{"key":"B25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis \u2013 etiologic agent of plague.","volume":"10","author":"Perry","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/annhyg\/32.inhaled_particles_VI.53","article-title":"Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals.","volume":"32","author":"Raabe","year":"1988","journal-title":"Ann. Occup. Hyg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jac\/41.4.461","article-title":"Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.","volume":"41","author":"Russell","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1358\/dot.2012.48.5.1789474","article-title":"Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.","volume":"48","author":"Serisier","year":"2012","journal-title":"Drugs Today"},{"key":"B29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1128\/IAI.01473-08","article-title":"Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.","volume":"77","author":"Thomas","year":"2009","journal-title":"Infect. Immun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3201\/eid0809.010536","article-title":"Biological warfare at the 1346 siege of caffa.","volume":"8","author":"Wheelis","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/10731190009118586","article-title":"Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylococcus aureus by murine macrophages.","volume":"28","author":"Wong","year":"2000","journal-title":"Artif. Cells Blood Substit. Biotechnol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0168-3659(03)00358-4","article-title":"Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection.","volume":"92","author":"Wong","year":"2003","journal-title":"J. Control. Release"},{"key":"B34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections.","volume":"85","author":"Zhou","year":"2015","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2017.00091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T10:34:48Z","timestamp":1568802888000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2017.00091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,6]]},"references-count":34,"URL":"https:\/\/doi.org\/10.3389\/fmicb.2017.00091","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,6]]}}}